Patents Assigned to UP THERAPEUTICS, INC.

Novel Spiro and Cyclic Bis-Benzylidine Proteasome Inhibitor for the Treatment of Cancer, Diabetes and Neurological Disorders

Publication number: 20210163420

Abstract: Described herein are spiro and cyclic bis-benzylidine proteasome inhibitors, which inhibit the proteasome function through either ubiquitin receptor ADRM1/RPN13 or proteasome DUB enzymes (USP14, UCH37 and RPN11), and which can be used for the treatment of cancers/diabetes/neurological disorders.

Type: Application

Filed: January 21, 2021

Publication date: June 3, 2021

Applicant: UP THERAPEUTICS, INC.

Inventor: Yung-Nien Chang
Spiro and cyclic bis-benzylidene proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders

Patent number: 10947199

Abstract: Described herein are spiro and cyclic bis-benzylidine proteasome inhibitors, which inhibit the proteasome function through either ubiquitin receptor ADRM1/RPN13 or proteasome DUB enzymes (USP14, UCH37 and RPN11), and which can be used for the treatment of cancers/diabetes/neurological disorders.

Type: Grant

Filed: January 30, 2018

Date of Patent: March 16, 2021

Assignee: UP THERAPEUTICS, INC.

Inventor: Yung-Nien Chang
Novel Spiro and Cyclic Bis-Benzylidene Proteasome Inhibitor for the Treatment of Cancer, Diabetes and Neurological Disorders

Publication number: 20190365726

Abstract: Described herein are spiro and cyclic bis-benzylidine proteasome inhibitors, which inhibit the proteasome function through either ubiquitin receptor ADRM1/RPN13 or proteasome DUB enzymes (USP14, UCH37 and RPN11), and which can be used for the treatment of cancers/diabetes/neurological disorders.

Type: Application

Filed: January 30, 2018

Publication date: December 5, 2019

Applicant: UP THERAPEUTICS, INC.

Inventor: Yung-Nien Chang

Novel Spiro and Cyclic Bis-Benzylidine Proteasome Inhibitor for the Treatment of Cancer, Diabetes and Neurological Disorders

Spiro and cyclic bis-benzylidene proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders

Novel Spiro and Cyclic Bis-Benzylidene Proteasome Inhibitor for the Treatment of Cancer, Diabetes and Neurological Disorders